These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

954 related items for PubMed ID: 30683630

  • 1. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J, Sun JM, Lee SH, Ahn JS, Park K, Choi Y, Ahn MJ.
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [Abstract] [Full Text] [Related]

  • 2. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ.
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [Abstract] [Full Text] [Related]

  • 3. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [Abstract] [Full Text] [Related]

  • 4. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF.
    J Clin Oncol; 2019 Jun 01; 37(16):1370-1379. PubMed ID: 30892989
    [Abstract] [Full Text] [Related]

  • 5. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT.
    Oncologist; 2019 Aug 01; 24(8):1103-1110. PubMed ID: 30890623
    [Abstract] [Full Text] [Related]

  • 6. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.
    Basit S, Ashraf Z, Lee K, Latif M.
    Eur J Med Chem; 2017 Jul 07; 134():348-356. PubMed ID: 28431340
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.
    Clin Cancer Res; 2016 Dec 15; 22(24):5983-5991. PubMed ID: 27401242
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
    Remon J, Pignataro D, Novello S, Passiglia F.
    Cancer Treat Rev; 2021 Apr 15; 95():102178. PubMed ID: 33743408
    [Abstract] [Full Text] [Related]

  • 12. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
    Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YL, Ock CY, Tchekmedyian N, Ou SI, Syn NL, Reungwetwattana T, Lin CC, Soo RA.
    J Thorac Oncol; 2020 Sep 15; 15(9):1484-1496. PubMed ID: 32360579
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
    Jóri B, Falk M, Hövel I, Weist P, Tiemann M, Heukamp LC, Griesinger F.
    Curr Oncol; 2022 Sep 16; 29(9):6628-6634. PubMed ID: 36135089
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
    Soo RA, Huat Tan E, Hayashi H, Seto T, Lin CC, Ou SI, Kim DW, Liu G, Abbattista A, Martini JF, Hooi Wong C, Toffalorio F, Solomon BJ.
    Lung Cancer; 2022 Jul 16; 169():67-76. PubMed ID: 35660971
    [Abstract] [Full Text] [Related]

  • 17. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Naito T, Shiraishi H, Fujiwara Y.
    Jpn J Clin Oncol; 2021 Jan 01; 51(1):37-44. PubMed ID: 33147606
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.